Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
Sorli, Christopher, Dr, Harashima, Shin-ichi, MD, Tsoukas, George M, MD, Unger, Jeffrey, MD, Karsbøl, Julie Derving, MD, Hansen, Thomas, PhD, Bain, Stephen C, Prof
Published in The lancet. Diabetes & endocrinology (01.04.2017)
Published in The lancet. Diabetes & endocrinology (01.04.2017)
Get full text
Journal Article